Peret Filho L A, Penna F J, Bambirra E A, Nicoli J R
Departamento de Pediatria, Faculdade de Medicina, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
J Med Microbiol. 1998 Feb;47(2):111-6. doi: 10.1099/00222615-47-2-111.
Survival, weight loss, translocation and histological alterations in the terminal ileum, liver and spleen were studied in mice simultaneously immunosuppressed with cyclophosphamide and treated or not with Saccharomyces boulardii until the death of all animals. The animals were divided into five groups: C1 (not immunosuppressed, not treated); C2 (immunosuppressed, not treated); B1 (immunosuppressed, treated with S. boulardii 10.0 mg); B2 (immunosuppressed, treated with S. boulardii 1.0 mg) and B3 (immunosuppressed, treated with S. boulardii 0.1 mg). Survival was higher in group B3 than in the other immunosuppressed groups. Weight loss was observed for all groups except C1. By day 7, some animals from each group were killed by ether inhalation for the determination of bacterial translocation and histopathological examination. Bacterial translocation to the liver was lower in groups C1 and B3 than in the other groups. The highest translocation to the liver and spleen was observed in group B1. Low S. boulardii translocation was observed in some animals, principally to the mesenteric lymph nodes. Histopathological examination showed a decrease in epithelial cell turnover with villus length reduction and loss of brush borders in group C2. Relative protection against these alterations was obtained when the animals were treated with the yeast, independently of the dose. Higher expression of the lymphoid component was also noted in the ileal lamina propria, liver and spleen of mice treated with the yeast, together with activation of the reticulo-endothelial system, when compared with group C2 where lymphocyte depletion was observed. This study suggests a relative protection of immunosuppressed animals by treatment with S. boulardii, but this phenomenon was inversely proportional to the yeast dose.
在同时用环磷酰胺进行免疫抑制且用或不用布拉酵母菌治疗直至所有动物死亡的小鼠中，研究了其存活率、体重减轻情况、细菌移位以及回肠末端、肝脏和脾脏的组织学改变。动物被分为五组：C1组（未免疫抑制，未治疗）；C2组（免疫抑制，未治疗）；B1组（免疫抑制，用10.0毫克布拉酵母菌治疗）；B2组（免疫抑制，用1.0毫克布拉酵母菌治疗）和B3组（免疫抑制，用0.1毫克布拉酵母菌治疗）。B3组的存活率高于其他免疫抑制组。除C1组外，所有组均观察到体重减轻。到第7天，每组的一些动物通过乙醚吸入处死，以测定细菌移位和进行组织病理学检查。C1组和B3组向肝脏的细菌移位低于其他组。向肝脏和脾脏的细菌移位在B1组中最高。在一些动物中观察到低水平的布拉酵母菌移位，主要是向肠系膜淋巴结。组织病理学检查显示C2组上皮细胞更新减少，绒毛长度缩短，刷状缘丧失。当动物用酵母治疗时，无论剂量如何，均可相对预防这些改变。与观察到淋巴细胞耗竭的C2组相比，在用酵母治疗的小鼠的回肠固有层、肝脏和脾脏中也观察到淋巴样成分的表达更高，同时网状内皮系统被激活。这项研究表明，用布拉酵母菌治疗可相对保护免疫抑制动物，但这种现象与酵母剂量成反比。
